<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1502">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716569</url>
  </required_header>
  <id_info>
    <org_study_id>SVU MED CIT0 23 4 21 1 120</org_study_id>
    <nct_id>NCT04716569</nct_id>
  </id_info>
  <brief_title>Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19</brief_title>
  <official_title>Faculty of Medicine ,South Valley University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many&#xD;
      authors according to many studies , covid virus stay in postnasal space for 4 days before&#xD;
      starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the&#xD;
      nose and post nasal space may help in early management of covid19 and may play a great rule&#xD;
      in prophylaxis as well&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 patient with early covid is devided into two groups first group will receive regular&#xD;
      protocol of drugs second group will receive ivermectin nasal spray in addition to regular&#xD;
      protocl of drugs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression of covid 19 clinical picture</measure>
    <time_frame>[ Time Frame: within 14 days after enrollement ]</time_frame>
    <description>progress of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)with radiological assesment and blood tests</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>intranasal Ivermectin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin group Patients who will receive intranasal ivermectin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients who will receive regular protocol drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal ivermectin spray</intervention_name>
    <description>usage of ivermectin as intranasal spray for treating early covid patiens</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>intranasal Ivermectin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  early covid19 pateints&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children and pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zaky Aref</name>
      <address>
        <city>QinƒÅ</city>
        <state>Qina</state>
        <zip>83511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaky Aref, MD</last_name>
      <phone>01001771210</phone>
      <email>doctor.aref@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>mohammed hosny hassaan, MD</last_name>
      <phone>00201115390073</phone>
      <email>mohammedhosnyhassaan@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0166354220302011</url>
    <description>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Zaky Aref</investigator_full_name>
    <investigator_title>ass.professor</investigator_title>
  </responsible_party>
  <keyword>Ivermectin intranasal spray in covid19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

